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Summary It is known that many solid animal tumours have a lower oxygenation level than most normal
tissues and, in addition, that this level of oxygenation can be further decreased by systemic administration of
5-hydroxytryptamine (5-HT). The present study has investigated if such selective decrease in tumour
oxygenation can be exploited by using the hypoxic cell cytotoxin, RSU-1069. The results obtained show that
5-HT at a dose of 5mgkg-1, although not cytotoxic alone, can potentiate the cytotoxic effects of RSU-1069
in the Lewis lung carcinoma over the dose range 0.01-0.15 mg g-1. Maximum potentiation occurs when 5-HT
is administered after RSU-1069. Potentiation of RSU-1069 cytotoxicity was observed using both the soft agar
excision assay as an endpoint as well as in situ growth delay. In addition, the study shows that potentiation of
RSU-1069 (0.1 mgg-) cytotoxicity can be seen with 5-HT doses as low as 0.5mgkg-1. In contrast to the
tumour cytotoxicity results, 5-HT at a dose of 5 mgkg - i.p. did not affect the systemic toxicity, as measured
by LD5oI7d of RSU-1069. Thus, these results indicate that 5-HT can increase the therapeutic efficiency of
RSU-1069. Such a finding is consistent with the rationale that selective reduction in tumour blood flow and
oxygenation induced by 5-HT can be exploited using the hypoxic cell cytotoxin RSU-1069.
It has been known for many years that systemic
administration of certain vasoactive drugs can
result in selective reductions in tumour blood flow
(Algire & Legallais, 1951; Cater et al., 1962; Cater
et al., 1963; Knapp et al., 1985). One of the most
effective agents in reducing blood flow to tumours
without affecting normal tissue blood flow is 5-
hydroxytryptamine (Cater et al., 1962; Cater et al.,
1963; Cater et al., 1965: Knapp et al., 1985).
The rationale for the present study was to
evaluate if this selective reduction in tumour blood
flow and thus oxygenation reported after adminis-
tration of 5-HT could be exploited therapeutically
using the 1-substituted 2-nitroimidazole RSU-1069.
This compound has been shown to be selectively
toxic to hypoxic cells both in vitro (Stratford et al.,
1986a) and in vivo (Chaplin et al., 1986).
Materials and methods
Mice and tumour
All experiments were performed using the Lewis
lung carcinoma growing in female C57B1/6 mice
(Charles River Inc.). The tumour has been
maintained by inoculation of tumour brei into the
gastrocnemius muscle. After 10 consecutive
passages, the tumour line was discarded and
subsequently renewed from frozen stock. Tumours
required for experimentation were derived by s.c.
injection of 105 to 106 viable tumour cells (obtained
by enzymatic digestion) over the sacral region of
the back and were used when the tumours attained
a mean diameter of 6-8 mm.
Preparation of tumour cell suspension
Tumours were excised 18-20h after drug treatment.
For each treatment group, 2-4 mice each bearing
one tumour were used. Following excision, the
tumours were pooled, washed with PBS chopped
using crossed scalpels and weighed. The resulting
fragments after being washed with PBS were dis-
aggregated by gentle agitation for 30min with an
enzyme cocktail of trypsin (0.1%), DNAse (0.05%)
and collagenase (0.02%). The resulting cell
suspension was filtered through polyester mesh
(50jum pore size), centrifuged and the cell pellet
resuspended in media. Cell suspensions were sub-
sequently counted on a haemocytometer enabling
tumour cell yield to be ascertained. The mean cell
yield for untreated tumours in the series of experi-
ments was 3.2 x 107 g1 of tissue (s.d. 1.0 x 107).
Measurement of tumour response
a) Soft agar clonogenic assay. This assay has been
described in detail previously (Courtenay, 1976).
Briefly, known numbers of tumour cells were plated
into soft agar cultured in a water saturated
atmosphere of 5%0 2, 5% CO2 and 90% N2 for 14
days. Tumour colonies of more than 50 cells were
counted with the aid of a microscope. For the
present series of experiments, the plating efficiency
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(PE=number of colonies counted/number of cells
plated) for untreated tumours was 5.8 x 10- (s.d.
+7 x 10-2).
The effect of treatment on cell survival was
expressed as the fraction of surviving cells per
tumour:
Fraction of surviving cells per tumour=
cell yieldg- ' treated
cell yieldg- 1 control
b) Growth delay Growth delay was determined
using groups of 6 mice, subjected to a range of drug
treatments and measuring the three orthogonal
diameters of each tumour three times a week until
they attained twice their original volume. The time
taken for the individual tumours in each dose group
to reach twice their original volume was
determined, thus enabling the mean (±s.e.) of the
time for each dose group to be calculated.
Drugs
RSU-1069 [1,(2-nitro-l-imadazolyl)-3-(1-aziridinyl)-
2-propanol] was supplied by Drs Adams, Stratford
and Jenkins (MRC Radiobiology Unit, Chilton,
Oxon, UK). In the present study, it was dissolved
in sterile saline and injected i.p. at 0.25ml per 25g
mouse.
5-HT (5-hydroxytryptamine, seretonin) was
obtained from Sigma (St. Louis, MO, USA), it was
dissolved in sterile saline and injected i.p. at 0.25ml
25g mouse.
Results
Figure 1 shows the response of the Lewis lung
carcinoma to various doses of RSU-1069. It can be
seen that RSU-1069 is cytotoxic to this tumour
with a surviving fraction of 2 x 10 1 being obtained
after administration of 0.1mgg-'. The effect of
5-HT on tumour cell survival is shown in Figure 2.
No significant cytotoxicity is observed after adminis-
tration of 5-HT alone in doses up to 5mgkg-'.
In the initial studies involving the administration
of both RSU-1069 and 5-HT, the importance of
drug scheduling was investigated by administering
5-HT (5mgkg-') at various times from 3h before
to 4h after RSU-1069 (0.1 mgg-'). From the results
obtained (Figure 3), it can be seen that the
maximum tumour cell kill is observed when 5-HT is
given after RSU-1069. Based on the results shown
in Figure 3, a schedule of administering 5-HT
60min after RSU-1069 was chosen as being
optimum for achieving tumour cell kill in the
present system and was used in all subsequent
studies.
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Figure 2 Cell survival as a function of 5-HT dose.
Figure 4 shows the effect of 5-HT (5mgkg-1)
administered 60min after various doses of RSU-
1069. The results indicate that over the dose range
studied (0.01-0.15mgg-1) the potentiation observed
is dose modifying. The effect of administration of
various doses of 5-HT (0.5-10mgkg-1) 60min after
RSU-1069 (0.1mgg-1) is shown in Figure 5. It can
be clearly seen that the potentiation increases with
increasing doses of 5-HT, however, these increases
appear to become maximal at a 5-HT dose of
2mgkg- .
Growth delay studies are shown in Figure 6. It
can be seen that the growth delay observed when 5-
HT (5mgkg-') is administered 60min after RSU-
1069 (0.1mgg-1) is greater than when either agent
is administered alone. The growth delay values
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Figure 3 The effect on cell survival of 5-HT
(5mgkg-1) when administered at various times before
(+) or after (-) RSU-1069 (O.lmgg-1) (---
0.1 mgg- I RSU-1069 alone).
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Figure 5 The effect of various doses of 5-HT
administered 60min after RSU-1069 (0.1mgg-1) on
Lewis lung tumour cell survival.
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Figure 4 The effect of 5-HT (5mgkg-1) administered
60min after a dose of RSU-1069 on Lewis lung
tumour cell survival (--- RSU-1069 alone from Figure
1).
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Figure 6 The effect of 5-HT (5mgkg-1), RSU-1069
(0.1 mgg-1) and 5-HT (5 mgkg-1) 60min after RSU-
1069 (0.1 mgg-1) on the growth of the Lewis lung
carcinoma. (E) untreated, (A) 5-HT alone, (A) RSU-
1069 alone, (A) 5-HT+ RSU-1069. Errors are +s.e.
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Table I Effect of 5-HT on LD507d of RSU-1069.
Number ofmice alive 7 days after treatment
Number ofmice in treatment group
Dose of RSU-1069 RSU-1069 5-HT (5mgkg 1) 60min
mgg-1 alone after RSU-1069
0.10 4/4 4/4
0.14 4/4 4/4
0.16 4/4 4/4
0.18 3/4 3/4
0.20 1/4 2/4
0.22 0/4 1/4
0.24 0/4 0/4
(±s.e.) obtained in this study were 1.9 (±1.1), 0.9
(±1.3) and 5.6 (±0.8) for RSU-1069 alone, 5-HT
alone and 5-HT+RSU-1069 respectively.
Although these tumour studies clearly indicate
that 5-HT can pontentiate the tumour cytotoxicity
of the hypoxic cell cytotoxin RSU-1069, such an
effect will only be therapeutically beneficial if
similar potentiation of systemic toxicity does not
occur. In order to assess systemic toxicity, the
LD5oI7d of RSU-1069 was determined both when
administered alone and when administered 60min
before 5-HT (5mgkg-1). It can be seen from the
results shown in Table I that 5-HT does not alter
the LD50/7d of RSU-1069. Thus, the potentiation of
RSU-1069 cytotoxicity by 5-HT is likely to be
tumour-specific.
Discussion
The basis of selective toxicity is to exploit
differences that exist between the normal host cell
population and the 'invading' cell population. To
date most of the therapies used in cancer treatment
are designed to exploit subtle differences in cellular
biochemistry and proliferation kinetics that exist
between normal and malignant cells. With the
exception of hyperthermia little attention has been
focussed on utilising the physiological differences
between normal and tumour tissue. In the present
study, we have evaluated the effect of combining a
drug known to selectively reduce tumour blood
flow (and thus oxygen delivery) with a drug known
to be preferentially toxic to cells at reduced oxygen
tensions.
The results in Figure 3 clearly indicate that 5-HT
can pontentiate the tumour cytotoxicity of RSU-
1069. However, the level of potentiation seen is
dependent on the scheduling of the two agents.
Little or no potentiation being observed if 5-HT is
administered before RSU-1069, whereas if 5-HT is
administered after RSU-1069 significant poten-
tiation of tumour cytotoxicity is seen. The absence
of potentiation when 5-HT is administered prior to
RSU-1069 probably reflects the fact that a 5-HT
induced reduction in tumour blood flow both at the
time of and immediately after RSU-1069 adminis-
tration would reduce the amount of RSU-1069
reaching the tumour. It has been reported that peak
plasma levels of RSU-1069 after i.p. delivery occur
within 5min of injection and then decrease with a
half-life of 22min (Workman & Walton, 1984).
Thus any reduction in tumour blood flow in the
first 30min after administration of RSU-1069
would dramatically reduce the tumour exposure to
this drug and hence cytotoxicity. The maximum
tumour cytotoxicity was observed in the present
study if 5-HT was administered 1-4h after RSU-
1069. The fact that 5-HT can potentiate tumour
cytotoxicity when administered 4h after RSU-1069,
at which time blood levels of RSU-1069 would be
negligible (Workman & Walton, 1984) indicates
that any 5-HT alteration of RSU-1069 pharmaco-
kinetics does not contribute to the potentiation of
tumour cytotoxicity seen in the present study. The
fact that RSU-1069 can bind to aerobic cells and
render them susceptible to cell killing during a
period of subsequent hypoxia (Stratford et al.,
1986b) may explain why potentiation of RSU-1069
tumour cytotoxicity is seen when 5-HT is adminis-
tered several hours afterwards.
Although the results obtained in the time course
study (Figure 3) demonstrate that 5-HT can
potentiate the cytotoxicity effects of a relatively
high dose of RSU-1069, i.e. 0.1 mgg-1, it is
important to know if this effect can be observed
with lower possibly clinically achievable doses of
RSU-1069. It can be seen from the data shown in
Figure 4 that 5-HT (5mgkg-1) can potentiate the
tumour cytotoxicity of RSU-1069 over a range of
RSU-1069 doses from 0.01 to 0.15mgg- . The
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RSU-1069 dose range studied giving an
enhancement ratio of - 4.0. The importance of 5-
HT dose on the potentiation observed is shown in
Figure 5. It can be seen that potentiation increases
with increasing doses of 5-HT up to 2mgkg-1.
However, increasing the dose above this does not
provide any significant increase in potentiation.
Such an effect could be explained by the results
reported by Cater and colleagues (1963) who
showed that 5-HT at a dose of 5mgkg-1
completely abolished tumour blood flow in their
tumour system. If such an effect occurred in the
Lewis lung tumour at a 5-HT dose of 2mgkg-1
then increasing the dose of 5-HT would not
increase the level of tumour hypoxia and thus no
further increase in potentiation of RSU-1069
tumour cytotoxicity would be observed. The
potentiation of RSU-1069 tumour cytotoxicity by
5-HT observed using the soft agar assay is also
observed using tumour growth delay as the
endpoint. Of particular importance are the results
shown in Table I. These show than no potentiation
of the systemic toxicity of RSU-1069 is observed
when 5-HT is administered 60min after RSU-1069.
The present study thus indicates that 5-HT can
selectively potentiate the tumour cytotoxicity of the
hypoxic cell cytotoxin RSU-1069 which would be
consistent with the reports that 5-HT selectively
reduces tumour blood flow (Cater et al., 1962:
Cater et al., 1963; Cater et al., 1965; Knapp et al.,
1985). Further studies are now required to
investigate the effects of combining agents known
to selectively reduce tumour blood flow with drugs
which are selectively toxic to hypoxic cells. Kruuv
and colleagues (1967) reported that several vaso-
dilators reduced tumour blood flow in their experi-
mental tumour systems. As a result of these
findings, the investigators stated that administration
of such compounds during radiotherapy or chemo-
therapy regimes would be unlikely to be of value.
However, with the recent development of drugs
which are known to be selectively toxic to hypoxic
cells (Adams et al., 1984; Zeman et al., 1986) this
statement may no longer be true. Indeed, the
combination of drugs known to be toxic to hypoxic
cells with those known to selectively reduce tumour
oxygenation may well represent a new approach to
selective tumour therapy.
I wish to acknowledge the excellent technical assistance
given to me by Doug Aoki and Nancy Arnold. This work
was supported by a grant from the National Cancer
Institute of Canada (NCIC).
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